Immunohistochemistry with IDH1 R132H mutant-specific antibodies is used as an alternative procedure for glioma classification, being particularly useful when direct sequencing cannot be implemented for economic or facility reasons or because of tissue resource limitations [2,7,9,14]. This evidence concerns the gene IDH1 and glioma.